Seres Therapeutics (MCRB) News Today $0.76 +0.03 (+3.45%) Closing price 04:00 PM EasternExtended Trading$0.74 -0.01 (-1.35%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Seres Therapeutics' (MCRB) "Buy" Rating Reiterated at Chardan CapitalMarch 23, 2025 | americanbankingnews.comChardan Capital Reaffirms Buy Rating for Seres Therapeutics (NASDAQ:MCRB)Chardan Capital reiterated a "buy" rating and set a $1.25 price objective on shares of Seres Therapeutics in a research report on Thursday.March 21, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of "Hold" from BrokeragesMarch 19, 2025 | americanbankingnews.comThe Goldman Sachs Group Issues Pessimistic Forecast for Seres Therapeutics (NASDAQ:MCRB) Stock PriceMarch 17, 2025 | americanbankingnews.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of "Hold" by BrokeragesSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has earned a consensus rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating toMarch 15, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Price Target Cut to $0.75 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group cut their price target on Seres Therapeutics from $1.00 to $0.75 and set a "sell" rating for the company in a research note on Friday.March 15, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2024 Earnings Call TranscriptMarch 14, 2025 | msn.comSeres Therapeutics (MCRB) Gets a Hold from Piper SandlerMarch 14, 2025 | markets.businessinsider.comSeres Therapeutics reports FY24 EPS (81c), consensus (20c)March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc.: Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | finanznachrichten.deSeres Therapeutics announces anticipated upcoming milestonesMarch 13, 2025 | markets.businessinsider.comSeres Therapeutics sees cash runway into 1Q26March 13, 2025 | markets.businessinsider.comSeres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comSeres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesMarch 13, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.comStockNews.com upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.March 7, 2025 | marketbeat.comSeres Therapeutics (MCRB) Expected to Announce Earnings on ThursdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.March 6, 2025 | marketbeat.comSeres Therapeutics receives feedback from FDA on SER-155 development approachMarch 4, 2025 | markets.businessinsider.comSeres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025March 4, 2025 | globenewswire.comSeres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development ApproachMarch 3, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Cut to Sell at StockNews.comStockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday.February 26, 2025 | marketbeat.comSeres Therapeutics (MCRB) to Release Earnings on TuesdaySeres Therapeutics (NASDAQ:MCRB) will be releasing earnings before the market opens on Tuesday, March 4.February 25, 2025 | marketbeat.comSeres Therapeutics EVP sells $2,704 in stockFebruary 22, 2025 | investing.comSeres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 SharesSeres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) CEO Eric D. Shaff sold 12,726 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $0.81, for a total value of $10,308.06. Following the sale, the chief executive officer now owns 192,039 shares of the company's stock, valued at $155,551.59. This trade represents a 6.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.February 20, 2025 | marketbeat.comSeres Therapeutics, Inc. (NASDAQ:MCRB) CEO Sells $10,308.06 in StockFebruary 20, 2025 | insidertrades.comVontobel Holding Ltd. Has $780,000 Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB)Vontobel Holding Ltd. grew its position in Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 137.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 938,295 shares of the biotechnology company's stockFebruary 19, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Upgraded to "Hold" at StockNews.comStockNews.com upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.February 15, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Share Price Passes Below 50 Day Moving Average - Time to Sell?Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.comSeres Therapeutics expands board, appoints new directorFebruary 6, 2025 | msn.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Below 50 Day Moving Average - Here's WhySeres Therapeutics (NASDAQ:MCRB) Share Price Crosses Below Fifty Day Moving Average - What's Next?January 28, 2025 | marketbeat.comSeres Therapeutics announces receipt of expected $50M installment paymentJanuary 16, 2025 | markets.businessinsider.comSeres Receives $50 Mln Installment Payment Towards Sale Of VOWST Business To Nestle Health ScienceJanuary 16, 2025 | markets.businessinsider.comSeres Therapeutics receives $50 million from Nestlé Health ScienceJanuary 16, 2025 | msn.comSeres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST SaleJanuary 16, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to "Sell"StockNews.com lowered shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.January 11, 2025 | marketbeat.comSeres Therapeutics (MCRB) Receives a Buy from TD CowenJanuary 10, 2025 | markets.businessinsider.comSeres announces new translational biomarker results from SER-155 Phase 1b studyJanuary 10, 2025 | finance.yahoo.comSeres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate UpdatesJanuary 9, 2025 | globenewswire.comSeres Therapeutics (NASDAQ:MCRB) Raised to Hold at StockNews.comStockNews.com upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.January 3, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Pass Above Fifty Day Moving Average - What's Next?Seres Therapeutics (NASDAQ:MCRB) Share Price Crosses Above 50-Day Moving Average - Time to Sell?January 2, 2025 | marketbeat.comThe past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitableDecember 26, 2024 | uk.finance.yahoo.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Below 200 Day Moving Average - Here's WhySeres Therapeutics (NASDAQ:MCRB) Stock Crosses Below Two Hundred Day Moving Average - What's Next?December 18, 2024 | marketbeat.comSeres Therapeutics to highlight plans for SER-155 at JPMorgan conferenceDecember 17, 2024 | finance.yahoo.comSeres Therapeutics to Participate in 2025 J.P. Morgan Healthcare ConferenceDecember 16, 2024 | globenewswire.comSeres’ SER-155 gains breakthrough status for BSIs reductionDecember 11, 2024 | finance.yahoo.comOptimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost ConfidenceDecember 11, 2024 | markets.businessinsider.comSeres Therapeutics to Participate in Piper Sandler Healthcare ConferenceNovember 22, 2024 | globenewswire.comSeres Therapeutics Reports Q3 2024 Results and Strategic ProgressNovember 15, 2024 | markets.businessinsider.comPromising Developments and Financial Stability Drive Buy Rating for Seres TherapeuticsNovember 15, 2024 | markets.businessinsider.comSeres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...November 15, 2024 | finance.yahoo.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.com Remove Ads Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address MCRB Media Mentions By Week MCRB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MCRB News Sentiment▼0.830.78▲Average Medical News Sentiment MCRB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MCRB Articles This Week▼52▲MCRB Articles Average Week Remove Ads Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TRVI News Today AKBA News Today ABVX News Today ALT News Today KROS News Today ORKA News Today PHAT News Today AUTL News Today TRML News Today STOK News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MCRB) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MCRB Stock Free MCRB Stock Alerts